Loading...
•
Dec 31, 2023
Organon Q4 2023 Earnings Report
Organon's Q4 2023 performance showcased revenue growth driven by Women's Health and Biosimilars, alongside improved profitability.
Key Takeaways
Organon reported an 8% increase in total revenue to $1,598 million for Q4 2023. The company's growth was primarily fueled by strong performances in Women's Health and Biosimilars segments. Net income increased significantly to $546 million, and adjusted EBITDA margin improved to 28.1%.
Total revenue increased by 8% to $1,598 million compared to Q4 2022.
Women's Health revenue grew by 7%, driven by fertility products and oral contraceptives.
Biosimilars revenue increased by 49%, led by Ontruzant and Renflexis.
Net income rose to $546 million, or $2.13 per diluted share, compared to $108 million, or $0.42 per diluted share, in Q4 2022.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Organon expects low-single-digit constant currency revenue growth and stable to improving Adjusted EBITDA margin for full year 2024.
Positive Outlook
- Expects constant currency revenue growth in the low-single-digit range.
- Expects stable to improving Adjusted EBITDA margin.
- Achieve stable to improving Adjusted EBITDA margin through operating expense management.
- Priorities are to deliver their third year of constant currency revenue growth
- Well positioned at the forefront of women's health effort.
Challenges Ahead
- Unable to reasonably predict certain items contained in the GAAP measures.
- Such items include acquisition related expenses.
- Such items include restructuring and related expenses
- Such items include stock-based compensation
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...